← Oncology Approval Tracker

FDA DECISION ·

Krazati + cetuximab

adagrasib with cetuximab · Mirati Therapeutics (Bristol Myers Squibb)

Accelerated approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Indication withdrawn on Sep 1, 2026

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with locally advanced or metastatic colorectal cancer with FDA test-confirmed KRAS G12C after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The combination targets KRAS G12C and EGFR signaling together in previously treated colorectal cancer. The FDA lists this indication as withdrawn in September 2026.

What research teams should watch

Verify the exact KRAS variant and all three required chemotherapy exposures; coordinate oral adherence and IV visits.

PRIMARY RECORDS

Sources